FI980947A - Pure 3R-3'R Stereoisomer of Zeaxanthin for Treatment of Ocular Yellow Spot Change - Google Patents

Pure 3R-3'R Stereoisomer of Zeaxanthin for Treatment of Ocular Yellow Spot Change Download PDF

Info

Publication number
FI980947A
FI980947A FI980947A FI980947A FI980947A FI 980947 A FI980947 A FI 980947A FI 980947 A FI980947 A FI 980947A FI 980947 A FI980947 A FI 980947A FI 980947 A FI980947 A FI 980947A
Authority
FI
Finland
Prior art keywords
zeaxanthin
stereoisomer
ocular
pure
treatment
Prior art date
Application number
FI980947A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI980947A0 (en
Inventor
Kevin M Garnett
Dennis L Gierhart
Luis H Guerrasantos
Original Assignee
Applied Food Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/551,153 external-priority patent/US5827652A/en
Priority claimed from US08/551,166 external-priority patent/US5854015A/en
Publication of FI980947A0 publication Critical patent/FI980947A0/en
Application filed by Applied Food Biotech Inc filed Critical Applied Food Biotech Inc
Publication of FI980947A publication Critical patent/FI980947A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI980947A 1995-10-31 1998-04-29 Pure 3R-3'R Stereoisomer of Zeaxanthin for Treatment of Ocular Yellow Spot Change FI980947A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/551,153 US5827652A (en) 1995-10-31 1995-10-31 Zeaxanthin formulations for human ingestion
US08/551,166 US5854015A (en) 1995-10-31 1995-10-31 Method of making pure 3R-3'R stereoisomer of zeaxanthin for human ingestion
PCT/US1996/017563 WO1997016175A1 (en) 1995-10-31 1996-10-30 Pure 3r-3'r stereoisomer of zeaxanthin for treating macular degeneration in humans

Publications (2)

Publication Number Publication Date
FI980947A0 FI980947A0 (en) 1996-10-30
FI980947A true FI980947A (en) 1998-04-29

Family

ID=27069666

Family Applications (1)

Application Number Title Priority Date Filing Date
FI980947A FI980947A (en) 1995-10-31 1998-04-29 Pure 3R-3'R Stereoisomer of Zeaxanthin for Treatment of Ocular Yellow Spot Change

Country Status (14)

Country Link
JP (1) JPH10512594A (en)
KR (1) KR100570251B1 (en)
CN (1) CN1104235C (en)
AR (1) AR004245A1 (en)
AU (1) AU710634B2 (en)
BR (1) BR9611488A (en)
CZ (1) CZ297575B6 (en)
FI (1) FI980947A (en)
HU (1) HU223208B1 (en)
NO (1) NO981698L (en)
PL (1) PL185465B1 (en)
RU (1) RU2197958C2 (en)
WO (1) WO1997016175A1 (en)
ZA (1) ZA969139B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088363B2 (en) 2002-10-28 2012-01-03 Zeavision Llc Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
GB0501365D0 (en) 2005-01-21 2005-03-02 Promar As Compositions
WO2006086706A2 (en) * 2005-02-11 2006-08-17 Kalamazoo Holdings, Inc. A capsicum variety exhibiting a hyper-accumulation of zeaxanthin and products derived therefrom
US8592662B2 (en) 2005-02-11 2013-11-26 Kalamazoo Holdings, Inc. Capsicum variety exhibiting a hyper-accumulation of zeaxanthin and products derived therefrom

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US308759A (en) * 1884-12-02 Curling hat-brims and machine therefor
DE69030817T2 (en) * 1989-08-30 1997-10-16 Applied Food Biotech Inc Process for the preparation of a composition containing zeaxanthin by means of a microorganism of the species Flavobacterium multivorum
US5310764A (en) * 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene

Also Published As

Publication number Publication date
WO1997016175A1 (en) 1997-05-09
KR100570251B1 (en) 2006-06-21
CN1201388A (en) 1998-12-09
HU223208B1 (en) 2004-03-29
FI980947A0 (en) 1996-10-30
PL326558A1 (en) 1998-09-28
AU7050196A (en) 1997-05-08
RU2197958C2 (en) 2003-02-10
KR19990067180A (en) 1999-08-16
NO981698D0 (en) 1998-04-16
PL185465B1 (en) 2003-05-30
CZ130998A3 (en) 1998-07-15
CN1104235C (en) 2003-04-02
CZ297575B6 (en) 2007-02-07
JPH10512594A (en) 1998-12-02
ZA969139B (en) 1997-09-25
NO981698L (en) 1998-06-08
BR9611488A (en) 1999-01-19
AR004245A1 (en) 1998-11-04
HUP9802314A3 (en) 1999-05-28
MX9605248A (en) 1998-06-30
AU710634B2 (en) 1999-09-23
HUP9802314A2 (en) 1999-04-28

Similar Documents

Publication Publication Date Title
NO965377L (en) Indolinone compounds for the treatment of diseases
ITMI942365A0 (en) RETINA FOR ORTHOPEDIC-TRAUMATOLOGICAL SURGERY
HK1023119A1 (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
AU1709699A (en) 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
AU2053597A (en) Pharmaceutical compositions for the treatment of glaucoma
AU5540594A (en) Method of performing ophthalmic surgery
PT754407E (en) LIQUID FORMULATIONS OF 1,2-BENZISOYLAZOLIN-3-ONA
AU5436198A (en) 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
FR2742331B1 (en) INSTRUMENT FOR THE EXECUTION OF ENDOSCOPIC THERAPY
NO20000062D0 (en) Prostaglandin derivatives free of side effects for the treatment of glaucoma
AU5258698A (en) 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension
ID16007A (en) METHODS FOR SEPARATION OF 2-HYDROXIC ACID-4-METHYL IOP BUTIRAT OR MHA
AU2211700A (en) Prostaglandin e agonists for treatment of glaucoma
AU2467395A (en) Novel ophthalmologic uses of protein c
IL125002A0 (en) Novel substituted 4-(1H-benzimidazol-2-yl) [1,4] diazepanes useful for the treatment of allergic diseases
FI980947A (en) Pure 3R-3'R Stereoisomer of Zeaxanthin for Treatment of Ocular Yellow Spot Change
AU2155995A (en) New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
IT1271567B (en) PROCEDURE FOR THE FURTHER TREATMENT OF SALCICCE
NO973366L (en) Procedure for the treatment of multiple sclerosis
AU3137095A (en) Ophthalmic compositions for treating glaucoma
AU5526196A (en) Compositions for the treatment of dandruff
NO942756D0 (en) Treatment of glaucoma
AU8883998A (en) Pharmaceutical compositions for the treatment of ocular inflammations comprisingdexamethasone palmitate
IT1277680B1 (en) PROCEDURE FOR THE ALKYLATION OF AROMATIC COMPOUNDS
AU5018893A (en) Substituted hydrindanes for the treatment of angiogenesis-dependent diseases

Legal Events

Date Code Title Description
FD Application lapsed